Biphenyl Compound LSD1 Inhibitor Structure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current LSD1 inhibitors lack selective and strong inhibitory activity, and existing compounds do not effectively target LSD1 for cancer and other LSD1-related diseases, such as Alzheimer's and Huntington's disease, due to their structural limitations and lack of specific activity.
Innovation Solution
A novel biphenyl compound with a specific structural configuration, including a benzene ring with an amide or thioamide group and an unsaturated hydrocarbon or heterocyclic ring, exhibits selective and strong LSD1 inhibitory activity, offering a potential therapeutic agent for cancers and other LSD1-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing LSD1 inhibitor compounds are used, then some inhibitory activity is achieved, but the inhibitory activity is not selective or strong enough for effective cancer therapy
Solution Approach 1:
The patent applies parameter changes by modifying specific structural parameters of LSD1 inhibitor compounds. The invention identifies key structural parameters (amide/thioamide group at position 4, substituent at position 3, and aromatic ring at position 5 of the pyridine ring) and optimizes them to achieve strong and selective LSD1 inhibitory activity. This systematic parameter optimization resolves the contradiction by finding the right balance between structural complexity and inhibitory effectiveness.
Solution Approach 2:
The patent employs composite material principles by combining multiple structural components into a unified compound structure. The inhibitor consists of a pyridine ring core composite with specific functional groups (amide/thioamide, nitro/cyano, halogen, alkoxy) and aromatic substituents. This composite structure achieves synergistic effects that enhance LSD1 inhibitory activity beyond what individual components could provide alone.
2Ease of manufacture
If compound structure is simplified for ease of manufacture, then manufacturing becomes easier, but LSD1 inhibitory activity is lost
Solution Approach 1:
The patent applies segmentation by dividing the complex LSD1 inhibitor into synthesizable modular components. The compound is structured with distinct functional modules (pyridine core, amide/thioamide group, aromatic substituent) that can be synthesized separately and then assembled through established chemical reactions. This modular segmentation enables easier manufacturing while preserving the complete inhibitory activity profile.
3Reliability
If existing therapeutic methods are used for intractable cancers, then treatment approaches are available, but satisfactory therapeutic effect cannot be achieved
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting the specific LSD1 enzyme as the therapeutic target, separating it from broader cancer therapy approaches. The compound is designed to specifically bind to and inhibit LSD1 demethylase activity, extracting the essential therapeutic function from complex cancer treatment mechanisms. This focused extraction achieves satisfactory therapeutic effects in intractable cancers by targeting the root epigenetic mechanism.
Data Source
AI summary
A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.